Kornélia Polyák

Harvard University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

106h-index77.2kcitations670works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(143), Cancer Cells and Metastasis(100), Epigenetics and DNA Methylation(90), Advanced Breast Cancer Therapies(75), Bioinformatics and Genomic Networks(58)

Publications668 total

Supplementary Table S9 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S3 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S8 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Figures from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S5 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S7 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S6 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S2 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S4 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
Supplementary Table S1 from JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
2025Open Access
METTL3-dependent m6A RNA methylation suppresses aberrant mammary epithelial differentiation and neoplastic transformation
Proceedings of the National Academy of Sciences·2025Open Access
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
The Lancet Oncology·2025· 11 cited
Abstract P1-03-30: Genomic risk score distribution and outcomes of patients with early-stage breast cancer diagnosed during pregnancy
Clinical Cancer Research·2025
Abstract P1-01-23: Oncotype DX Breast Recurrence Score® distribution and prognostic value according to prior pregnancy status in young women with breast cancer
Clinical Cancer Research·2025
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavage
Nature Genetics·2025· 4 citedOpen Access
Impact of pregnancy history and recency of childbirth on long-term outcomes in young patients with early-stage breast cancer.
Journal of Clinical Oncology·2025
Associations of circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with the expression of stem cell markers in benign breast tissue
Breast Cancer Research·2025· 1 citedOpen Access
Epigenetic drivers of metalloproteinases and metastasis
Trends in Cell Biology·2025· 3 citedOpen Access
The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer
npj Breast Cancer·2024· 2 citedOpen Access
ZBTB7A is a modulator of KDM5-driven transcriptional networks in basal breast cancer
Cell Reports·2024· 7 citedOpen Access
page 1 of 34Next →

Frequent Co-authors

Kenneth W. Kinzler(8), Bert Vogelstein(8), Joan Massagué(7), Andriy Marusyk(6), Michail Shipitsin(5), William C. Hahn(5), Robert A. Weinberg(4), Andrea L. Richardson(4), Tatiana Nikolskaya(4), Yuri Nikolsky(4), Victor E. Velculescu(4), Vanessa Almendro(4), Jun Yao(4), Mary W. Brooks(3), Lauren L. Campbell(3), James K. V. Willson(3), Saraswati Sukumar(3), Sanford D. Markowitz(3), Andrew Koff(3), James M. Roberts(3)